Compare Amgen, Inc. (AMGN) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Occidental Petroleum Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Occidental Petroleum Corporation trades at $53.56 (market cap $52.61B). The key difference: Amgen, Inc. is far larger — about 3.7× Occidental Petroleum Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | OXY | |
|---|---|---|
Market Cap | $196.12B | $52.61B |
Sector | Health | Energy |
52-Week High | $388.16 | $66.24 |
52-Week Low | $271.18 | $38.92 |
Enterprise Value | $241.41B | $73.69B |
Dividend Yield | 2.77% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Occidental Petroleum (OXY) trades at $52.89, up 1.13% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust profitability with a 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent news highlights rising oil prices from Middle East tensions boosting realized prices, while debt reduction and CrownRock asset integration remain focal points.
Outlook is mixed: analyst consensus is bullish with a $65.86 price target (50% buy ratings), but high P/E of 71.47 suggests premium valuation. Key opportunities include oil price leverage and carbon capture initiatives; risks involve oil volatility, debt levels, and execution under new CEO Richard Jackson. Cash flow trends show variability, with 2026 projecting positive net cash flow of $1.2B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
